Compare PNR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNR | ABVX |
|---|---|---|
| Founded | 1966 | 2013 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.9B |
| IPO Year | 2003 | 2022 |
| Metric | PNR | ABVX |
|---|---|---|
| Price | $61.59 | $113.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $109.73 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 2.7M | 818.6K |
| Earning Date | 04-28-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 5.88 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | $52.14 |
| Revenue Next Year | $4.82 | $4,132.27 |
| P/E Ratio | $58.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.60 | $69.81 |
| 52 Week High | $113.95 | $148.83 |
| Indicator | PNR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 38.86 |
| Support Level | $57.60 | $107.67 |
| Resistance Level | $77.03 | $129.00 |
| Average True Range (ATR) | 1.85 | 3.46 |
| MACD | -0.28 | -0.85 |
| Stochastic Oscillator | 2.56 | 7.56 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.